Article Text

Download PDFPDF
Camel Crush pack inserts cross-promote Vuse menthol e-cigarettes ahead of impending menthol cigarette ban
  1. Daniel P Giovenco1,
  2. Ollie Ganz2,3,
  3. Julia Chen-Sankey2,3,
  4. Cristine D Delnevo2,3
  1. 1 Department of Sociomedical Sciences, Columbia University Mailman School of Public Health, New York, New York, USA
  2. 2 Rutgers Center for Tobacco Studies, Rutgers Biomedical and Health Sciences, New Brunswick, New Jersey, USA
  3. 3 Department of Health Behavior, Society and Policy, Rutgers School of Public Health, Piscataway, New Jersey, USA
  1. Correspondence to Dr Daniel P Giovenco; dg2984{at}cumc.columbia.edu

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Over the last several decades, the tobacco industry has grown considerably more consolidated due to a string of notable company mergers and acquisitions, with a particular emphasis on non-combustible products.1 As a result, a handful of multinational corporations maintain a diverse suite of tobacco products under dozens of brand names. For example, Altria—via subsidiaries—is the parent company for top brands including Marlboro cigarettes, Black & Mild cigars, Copenhagen smokeless tobacco and IQOS heated tobacco products. In March 2023, Altria also acquired all products in NJOY’s e-vapour portfolio after a $2.75 billion investment. Meanwhile, British American Tobacco (BAT) and its subsidiaries oversee US operations of Newport and Camel cigarettes, Grizzly smokeless tobacco and Vuse e-cigarettes.

Portfolio diversification across product categories was historically a way for tobacco companies to increase profits, pool resources, leverage relationships with retailers and expand into new consumer markets.1 Today, diversification is particularly critical to minimise profit loss amid a global decline in smoking and tightening cigarette regulations.2 Big Tobacco has heavily invested in the development …

View Full Text

Footnotes

  • X @dannygiovenco

  • Contributors DPG took primary responsibility for conceptualisation and writing. OG, JC-S and CDD contributed substantially to writing and critically revising the manuscript.

  • Funding This work was supported by grants from the National Cancer Institute (U54CA229973) and the Office of the Director (DP5OD023064) of the National Institutes of Health (NIH). The content does not necessarily represent the official views of the NIH.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.